Non-Hodgkin Lymphoma | Specialty

CHMP Recommends Approval of Obinutuzumab for Follicular Lymphoma

April 29th 2016

Obinutuzumab (Gazyva) has received a positive recommendation from the EMA’s Committee for Medicinal Products for Human Use for use in combination with bendamustine as a treatment for patients with follicular lymphoma who previously received chemotherapy.

Dr. Andre Goy Explains Marginal Zone Lymphoma

March 31st 2016

Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses marginal zone lymphoma.

Dr. John Leonard on Treatment Options for Relapsed Follicular Lymphoma

March 20th 2016

John Leonard, MD, medical oncology, at Weill Cornell Medicine and NewYorkPresbyterian Hospital, discusses follicular lymphoma treatment considerations. Treatment options include rituximab and bendamustine, which have been around for sometime, as well as newer agents like obinutuzumab, says Leonard.

Genomics Help Customize Therapy in Non-Hodgkin Lymphoma

March 19th 2016

With the R-CHOP chemotherapy regimen considered the backbone of therapy for treatment-naïve patients with non-Hodgkin lymphoma, researchers are now delving further into the genome to pave the way for therapeutic improvements.

Novel Agents on Horizon for Follicular Lymphoma

March 18th 2016

A host of novel agents are on the horizon that could further improve the long-term outcomes experienced by patients with follicular lymphoma, particularly those with relapsed or refractory disease.

Frontline Ibrutinib Highly Effective Across Subgroups for Elderly Patients With CLL/SLL

March 18th 2016

Frontline treatment with ibrutinib reduced the risk of progression or death by 84% compared with single-agent chlorambucil for elderly patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

New Agents Transform Treatment of Non-Hodgkin Lymphoma

March 16th 2016

Mitchell Smith, MD, discusses advancements in the field of non-Hodgkin lymphoma.

Dr. Peter Martin on Future Treatment Approaches in Mantle Cell Lymphoma

March 15th 2016

Peter Martin, MD, associate professor of Medicine, Division of Hematology/Oncology, Weill Cornell Medicine, predicts future treatment approaches in the field of mantle cell lymphoma (MCL).

CAR T-cell Therapies Effective Across Hematologic Malignancies

March 2nd 2016

Chimeric antigen receptor-modified T-cell therapies continue to demonstrate promising signs of efficacy for patients with hematologic malignancies, including those with acute lymphoblastic leukemia and non-Hodgkin lymphoma.

FDA Approves Obinutuzumab for Follicular Lymphoma

February 26th 2016

The FDA approved obinutuzumab (Gazyva) plus bendamustine followed by obinutuzumab alone for the treatment of patients with follicular lymphoma who were not responsive to a rituximab regimen, or who relapsed after rituximab-based therapy.

Blinatumomab Nears 70% Response Rate in Non-Hodgkin Lymphoma

February 18th 2016

The anti-CD19 agent blinatumomab (Blincyto) induced a response rate of 69% in patients with non-Hodgkin Lymphoma.

SYK Inhibitor Shows Promise in CLL

February 18th 2016

Entospletinib (GS-9973) has shown early promise as a treatment for pretreated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Dr. Yasenchak on Brentuximab Vedotin Added to R-CHOP in DLBCL

February 17th 2016

Christopher A. Yasenchak, MD, associate chair of Hematology Research, Willamette Valley Cancer Institute and Research Center/US Oncology Research, discusses results of a study examining the addition of brentuximab vedotin to R-CHOP for the treatment of patients with diffuse large B-cell lymphoma.

Allogeneic CAR T-Cell Therapy Shows Promising Efficacy Without GVHD

January 29th 2016

Treatment with allogeneic anti–CD19 chimeric antigen receptor–modified T cell therapy induced complete remissions in 30% of patients with advanced progressive B-cell malignancies without causing graft-versus-host disease.

Tackling Challenging Patient Populations in DLBCL

January 21st 2016

Kathryn Kolibaba, MD, discusses the significance of the PYRAMID and other studies, and how she hopes the treatment paradigm for diffuse large b-cell lymphoma will evolve in the future.

Future Strategies in the Treatment of Follicular Lymphoma

January 18th 2016

Novel Treatment Approaches in Follicular Lymphoma

January 18th 2016

Combining Targeted and Immunotherapeutic Agents in FL

January 18th 2016

The Role of Ibrutinib in Follicular Lymphoma

January 18th 2016

Monoclonal Antibodies in Follicular Lymphoma

January 18th 2016